Cabozantinib for the treatment of solid tumors: a systematic review

BACKGROUND: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence and the real-world performance of cabozantinib co...

Descripción completa

Detalles Bibliográficos
Autores principales: Maroto, Pablo, Porta, Camillo, Capdevila, Jaume, Apolo, Andrea B., Viteri, Santiago, Rodriguez-Antona, Cristina, Martin, Lidia, Castellano, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284205/
https://www.ncbi.nlm.nih.gov/pubmed/35847482
http://dx.doi.org/10.1177/17588359221107112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284205/
https://www.ncbi.nlm.nih.gov/pubmed/35847482
http://dx.doi.org/10.1177/17588359221107112

Ejemplares similares